Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Overview

Chronic obstructive pulmonary disease has become a serious global health care and public health problems due to its high prevalence, high morbidity and heavy economic burden. Acute exacerbation of chronic obstructive pulmonary disease is one of the most important causes of death in patients with COPD. Systemic corticosteroids therapy is recommended in COPD exacerbations. In clinical practice for the treatment of acute exacerbation of COPD, antibiotic application is still controversial. Evidence from current guideline is based on strict criteria from randomized controlled trials, thus the given condition is simplified. Patients meet the criteria account for the minority in the real world. Therefore, it is still not clear whether most patients benefit from the recommended treatment. In our design, hospitalized patients with acute exacerbation of COPD will be enrolled, with their treatment, arterial hypoxemia, recovery time and length of hospitalization being observed. The main purpose is to evaluate the benefit effect of current recommended treatment of acute exacerbation of COPD in the real world.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2015

Detailed Description

Chronic obstructive pulmonary disease has become a serious global health care and public health problems due to its high prevalence, high morbidity and heavy economic burden. Acute exacerbation of COPD is one of the most important causes of death in patients with COPD. The global strategy for the diagnosis, management, and prevention of COPD recommends systemic corticosteroids therapy in COPD exacerbations as it can shorten recovery time, reduce treatment failure, improve lung function and arterial hypoxemia. In clinical practice for the treatment of acute exacerbation of COPD, antibiotic application is still controversial. Evidence from current guideline is based on strict criteria from randomized controlled trials, thus the given condition is simplified. Patients meet the criteria account for the minority in the real world. Therefore, it is still not clear whether most patients benefit from the recommended treatment. In our design, hospitalized patients with acute exacerbation of COPD will be enrolled, with their treatment, arterial hypoxemia, recovery time and length of hospitalization being observed. The main purpose is to evaluate the benefit effect of current recommended treatment of acute exacerbation of COPD in the real world.

Clinical Trial Outcome Measures

Primary Measures

  • change of the score of COPD Assesment Test as a measurement of the overall condition of the patient
    • Time Frame: baseline, 1 month after dischahge, 2 months after discharge

Secondary Measures

  • change of the score of modified Medical British Research Council questionaire as a measurement of the overall condition of the patient
    • Time Frame: baseline, 1 month after discharge, 2 months after discharge

Participating in This Clinical Trial

Inclusion Criteria

  • Hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease
  • Age≥ 40years old

Exclusion Criteria

  • The first diagnosis which caused hospitalization is not acute exacerbation of chronic obstructive pulmonary disease
  • Chest radiography shows congestive heart failure
  • Chest CT shows lung cancer, active pulmonary tuberculosis, pulmonary thromboembolism or interstitial lung diseases
  • Serious cardiac failure, renal insufficiency or hepatic dysfunction

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Chao Yang Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Wang Ying, resident – Beijing Chao Yang Hospital
  • Overall Official(s)
    • Wang Ying, Master, Principal Investigator, Beijing Chao Yang Hospital
    • Huang Kewu, M.D., Study Chair, Beijing Chao Yang Hospital
  • Overall Contact(s)
    • Huang Kewu, M.D., 86-10-85231167, kewuhuang@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.